Buy Ipratropium Bromide (Atrovent) online
How and where to order Atrovent (Ipratropium Bromide) inhalation aerosol 20 mcg / dose online:
Indications and usage:
Dosage and administration:
Dosage forms and strengt:
Warnings and precautions:
Adverse reactions, side effects:
Most common adverse reactions ( > 5% incidence in the 12-week placebo-controlled trials) of Atrovent were bronchitis, COPD exacerbation, dyspnea, and headache.
To report suspected side effects of Atrovent (Ipratropium Bromide) inhalation aerosol and nasal spray contact Boehringer Ingelheim pharmaceutical company, or your local FDA.
Anticholinergics: may interact additively with concomitantly used anticholinergic medications. Avoid administration of Atrovent (Ipratropium Bromide) with other anticholinergic-containing drugs.
Patient counseling information:
Appropriate and safe use of Atrovent HFA (Ipratropium Bromide) includes providing the patient with the information listed below and an understanding of the way it should be administered.
Advise patients that Atrovent HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response.
Inform patients that hypersensitivity reactions, including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema, may occur after the administration of ipratropium bromide. Advise patients to immediately discontinue Atrovent HFA and consult a physician.
Inform patients that this drug can produce paradoxical bronchospasm that can be life-threatening. If paradoxical bronchospasm occurs, patients should discontinue using Atrovent HFA.
Caution patients to avoid spraying the aerosol into their eyes and be advised that this may result in precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion. Patients should also be advised that should any combination of these symptoms develop, they should consult their physician immediately.
Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with use of Ipratropium Bromide (Atrovent HFA), patients should be cautioned about engaging in activities requiring balance and visual acuity such as driving a car or operating appliances or machinery.
Inform patients that this medication may cause urinary retention and should be advised to consult their physicians if they experience difficulty with urination.
Frequency of use
The action of Atrovent HFA should last 2 to 4 hours. Advise patients not to increase the dose or frequency of ipratropium bromide without patients consulting their physician. Advise patients to seek immediate medical attention if treatment with this medicine becomes less effective for symptomatic relief, their symptoms become worse, and/or patients need to use the product more frequently than usual.
Concomitant drug use
Advise patients on the use of Atrovent HFA in relation to other inhaled drugs.
Use only as prescribed
Remind patients that Atrovent HFA (Ipratropium Bromide) should be used consistently as prescribed throughout the course of therapy.
Preparation for use and priming
Instruct patients that priming Atrovent HFA is essential to ensure appropriate content of the medication in each actuation. Patients do not have to shake the canister with this drug before use.
Where to buy ipratropium bromide online:
To purchase Atrovent (Ipratropium Bromide) inhalation aerosol from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing ipratropium bromide as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
Copyright © 1995 - 2022 AsthmAction by Merck & Co., Inc. All Rights Reserved.